The death of a patient in a trial of an experimental gene therapy casts new shadows over a technology once seen as the future ...

CHICAGO -- Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

The U.S. FDA has paused Rocket Pharmaceuticals' mid-stage gene therapy trial after a patient died from serious complications, ...

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of ...

An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), ...

Infant With Rare, Incurable Disease Is First to Successfully Receive Personalized Gene Therapy Treatment May 15, 2025 — A research team has developed and safely delivered a personalized gene ...

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett ...

A team of scientists from the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, has identified a ...

For gene therapy to work well, therapeutic molecules need to be efficiently delivered to the correct locations in the body -- a job commonly given to adeno-associated viruses (AAV). To improve the AAV ...